Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text

Medicine, Oncology, Radiation Oncology +15

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pieter E. Postmus, Keith M. Kerr, Matthijs Oudkerk et al. · Annals of Oncology · 2017 · 2.3K citations · Full text

Medicine, Oncology, Surgery +14

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

Liufu Deng, Hua Liang, Byron Burnette et al. · Journal of Clinical Investigation · 2014 · 2.1K citations

Medicine, Immunology, Oncology +17

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text

Medicine, Oncology, Radiation Oncology +17